Everything below concerns clinical endpoint. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-03-30. Numbers and descriptions here follow the published literature rather than marketing material.
The name itself causes confusion, because several unrelated thymic peptides share the thymosin label. Thymosin beta-4, for example, is a different molecule with different functions. Naming conventions in the literature also mix descriptive research terms with assigned nonproprietary names, so a reader should confirm which entity a given paper addresses. Clarifying that point is usually the first step in interpreting any claim about this peptide.
Thymosin alpha-1 is a short peptide of 28 amino acid residues first described in the 1970s as a component of thymic extracts. Its N-terminal residue carries an acetyl group, and the sequence is highly conserved across mammalian species. The peptide is not encoded as a standalone gene product; it is released by proteolytic cleavage from the N-terminus of prothymosin alpha, a larger acidic nuclear protein. That precursor relationship places it within a broader family of thymic and immune-associated peptides that have been studied for decades.
Lyophilized material is typically treated as a hygroscopic solid that should be brought to room temperature before the container is opened, which limits condensation on the powder. Reconstitution is commonly done with sterile water or a buffered diluent, and gentle mixing is preferred over vigorous agitation to reduce foaming and surface adsorption. Because peptides can bind to plastic and glass, diluents containing a small amount of carrier protein are sometimes used in laboratory work. Working solutions are generally aliquoted and prepared fresh rather than subjected to repeated freezing and thawing.
Stability depends on temperature, pH, and the number of freeze-thaw events the sample has experienced. Freeze-dried material is commonly held at -20 °C or colder, while reconstituted liquid is kept cold and used within a short window. Extreme pH and prolonged light exposure can promote deamidation, oxidation, or aggregation, particularly at asparagine and methionine positions. Adsorption to container walls can lower the measured concentration of a dilute solution even when the peptide molecules themselves remain intact.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography, which separates the target peptide from truncated or chemically modified byproducts. Mass spectrometry confirms the expected molecular mass and can indicate acetylation state or sequence errors. Amino acid analysis and peptide mapping supply complementary sequence-level information, while endotoxin testing is relevant for preparations intended for cell or animal work. Purity figures reported by suppliers refer to the method used and are not directly comparable across laboratories unless conditions are stated.
| Property | Value | Notes |
|---|---|---|
| Residue count | 28 amino acids | Acetyl group on the first residue |
| Approximate molecular mass | 3108 daltons | Calculated from the consensus sequence |
| Origin | Cleavage product of prothymosin alpha | Not encoded as a separate gene product |
| Primary research focus | Immune modulation | Studied in viral hepatitis and as a vaccine adjuvant |
| Common synonyms | Thymalfasin, Tα1, thymosin alpha 1 | Thymalfasin is the assigned nonproprietary name |
Several names appear in the literature for this peptide, including thymalfasin and the abbreviation T-alpha-1. Naming conventions differ among research articles, regulatory documents, and supplier catalogs, which complicates literature searches. Both synthetic and recombinant production routes yield a peptide with the same 28-residue sequence as the thymic isolate. Because the thymosin label also covers unrelated peptides, sources should be compared by sequence rather than by name alone.
The peptide occurs naturally in thymic tissue and has been detected in serum and other biological fluids. Reported concentrations are low, and reliable measurement generally requires immunoassay or mass spectrometry with an enrichment step. It is released from a larger precursor, prothymosin alpha, by proteolytic cleavage, although the enzymes involved are not fully characterized. Whether circulating levels reflect thymic output specifically remains an open question.
Thymosin alpha 1 is a 28-amino-acid peptide first isolated from thymosin fraction 5, a bovine thymic extract. Its sequence begins with an acetylated serine residue and carries a high proportion of acidic residues, so the molecule has a net negative charge near neutral pH. Despite the shared name, it is unrelated in sequence to the thymosin beta family. Synthetic material prepared by solid-phase peptide synthesis is identical in sequence to the natural peptide.
Thymosin alpha 1 was identified in 1977 as a component of thymosin fraction 5, a heterogeneous preparation used in early studies of thymic function. Investigators purified the active material and determined its amino acid sequence, which enabled chemical synthesis. Work in the following decades concentrated on T-cell maturation and immune reconstitution in animals and small human cohorts. Early preparations varied in composition, so results from that period are difficult to compare with studies using defined synthetic peptide.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Findings across trials are mixed; some report changes in selected immune markers, while others find no clear clinical benefit. Many studies are small and define outcomes differently, which limits comparison. Regulatory approval is confined to a few countries, and the compound is not an approved drug in the United States or most of Europe.
Overall evidence quality varies considerably. A large share of published reports come from single centers, rely on surrogate immunological markers, or lack adequate control groups. Systematic reviews have highlighted this heterogeneity as a barrier to pooling results. Open questions include which patients, if any, might benefit, what treatment duration is appropriate, and whether any effect is independent of standard care. The peptide is often described as an immune modulator rather than a therapy for one disease, which complicates confirmatory trial design.
=== Interactions with Solvent === Increasing addition of solute will alter the solvent's viscosity and polarizability, which cannot be measured by instruments that rely on low viscosity. Since differential refractometer is an external tool, the solvent viscosity does not pose a physical barrier to measurement, making them universal detectors.
Also, to bring the buildings up to the District of Columbia's current building code, the buildings required new plumbing, new electrical, HVAC, water, and fire suppression systems, new accessibility features for the disabled (including in one elevator), and the renovation has found higher levels of asbestos and a higher water table than was expected while also finding lead contamination in the ground underneath the buildings (which was not anticipated). Powell and the Federal Reserve have denied that the building designs included dining rooms or elevators for use only by VIPs or Federal Reserve Governors, rooftop terraces, and have asserted that the only proposed water features that had been included in the initial renovation plan for the East Building were eliminated. Additionally, both the East Building and the Eccles Building are included in the District of Columbia Inventory of Historic Sites while the East Building is also included in the National Register of Historic Places, and some of the cost overruns are due to changes to the design plans to comply with historic preservation laws for maintaining historic buildings and their appearance. The Eccles Building and East Building are also located on the National Mall, and the District's building code has a height restriction that requires that buildings not be taller than the United States Capitol, which required underground construction to expand one of the buildings to include a basement and an addition to the other for greater office space.
=== Commercial applications === According to a 2010 survey, the three primary uses of the 26,000 low-energy particle accelerators operating worldwide are radiotherapy (44%), ion implantation (41%), and industrial processing (9%). HVEC made foundational contributions to all three. The company's compact Van de Graaff generators were among the first artificial radiation sources commercially available for cancer treatment. Radiation physicist Milford Schulz called them "truly milestones in the progress of radiotherapy." The first medical linear accelerator—now the dominant technology in cancer treatment—was assembled at Stanford using a retrofitted HVEC machine. Ion implantation, pioneered at HVEC's Ion Physics Corporation, became standard practice in semiconductor manufacturing by the late 1970s. The technique enabled MOS integrated circuits that dominate modern electronics. Radiation crosslinking, developed at Electronized Chemicals Corporation, produced heat-shrink tubing and films now ubiquitous in electrical wiring and food packaging.
Sources: en.wikipedia.org
== Revival == The African Renaissance has been taken up as part of the International Decade for People of African Descent from 2015 to 2024, in which the Door of Return Initiative seeks to bring members of the African diaspora back to the continent. The initiative is spearheaded by the historical Maroon community of Accompong, Jamaica, in cooperation with Nigeria, Ghana, and Zimbabwe.
For example, the construction of multi-micron structures into larger architectures was accomplished using “criss-cross” polymerization. In this case, the additive components are “slats” instead of bricks. These slats have binding domains that allow them to attach perpendicularly to form a cross-linked structure. This approach stabilizes the structure, allowing for larger, highly ordered structures to form. This concept further reinforces the concept of smaller DNA components used as Legos to create larger structures without a bottom-up design. This approach also contrasts with earlier DNA origami techniques which relied on intricate computer software to design the scaffold and staple strands to enable creation of larger DNA nanostructures.
A stability diagram may be generated by calculating the matrix trace for each axis over a defined range of q and a values. The stability diagram of a square wave is very similar to that of the traditional harmonic quadrupole field. Having the additional parameter d in the waveform, the digital ion trap can perform certain experiments which are not available in the conventional harmonic wave RF ion trap. One example is the digital asymmetric wave isolation which is the method of using a d value around 0.6 to narrow the mass range to isolate a precursor ion. The DIT is a versatile instrument because it is capable of operating at constant AC voltage without a DC offset for any conceivable duty cycle and frequency. The dynamic frequency does not impose a limit on the mass range. The Mathieu space stability diagram of the linear and 3D DIT change with duty cycle. When a = 0 there will be a finite range of stable q values for each quadrupole axis that will depend on the duty cycle. Fig 3 (a) shows a Mathieu space stability diagram for the duty cycle d = 0.50 of a linear DIT. The horizontal line indicates where the parameter a = 0. The range of completely stable q values appear where this line passes through the green colored region; it ranges from q = 0 to roughly q = 0.7125. The blue colored areas in the figure depict stability along the x-axis only. Yellow colored regions depict stability along the y-axis only.
Bucillamine is an antirheumatic agent developed from tiopronin. Activity is mediated by the two thiol groups that the molecule contains. Research done in USA showed positive transplant preservation properties. Bucillamine is currently being investigated for COVID-19 drug repurposing. Bucillamine has a well-known safety profile and is prescribed in the treatment of rheumatoid arthritis in Japan and South Korea for over 30 years. It is a cysteine derivative with 2 thiol groups that is 16-fold more potent than acetylcysteine (NAC) as a thiol donor in vivo, giving it vastly superior function in restoring glutathione and therefore greater potential to prevent acute lung injury during influenza infection. Bucillamine has also been shown to prevent oxidative and reperfusion injury in heart and liver tissues. Bucillamine has both proven safety and proven mechanism of action similar to that of NAC, but with much higher potency, mitigating the previous obstacles to using thiols therapeutically. It is hypothesized that similar processes related to reactive oxygen species (ROS) are involved in acute lung injury during nCov-19 infection, possibly justifying the investigation of bucillamine as an intervention for COVID-19. On July 31, 2020, the U.S. Food & Drug Administration (FDA) has approved Revive Therapeutics Ltd. to proceed with a randomized, double-blind, placebo-controlled confirmatory Phase 3 clinical trial protocol to evaluate the safety and efficacy of Bucillamine in patients with mild-moderate COVID-19.
Sources: en.wikipedia.org
It is usually classified as an immunomodulatory peptide rather than a classical hormone. It derives from the larger protein prothymosin alpha and acts mainly on immune cells. The thymosin label covers a group of distinct peptides, so the naming can be misleading.
The two share a family name but have different sequences, sizes, and functions. Thymosin beta-4 is a 43-residue peptide associated with actin binding and cell migration. Thymosin alpha-1 is a 28-residue peptide linked mainly to immune signaling.
Thymalfasin is the assigned international nonproprietary name for the synthetic 28-residue peptide. Thymosin alpha-1 is the descriptive research name for the same molecule. Which term appears depends on the context and the regulatory document.
Cold storage slows the chemical degradation reactions that occur in solution. Lyophilized powder is more stable than reconstituted liquid and tolerates longer storage periods. Repeated temperature cycling should still be avoided because it can drive aggregation and loss of material.